Article

Pneumococcal bacteremia in a vaccinated pediatric sickle cell disease population.

Division of Emergency Medicine, The Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
The Pediatric Infectious Disease Journal (Impact Factor: 3.14). 01/2012; 31(5):534-6. DOI: 10.1097/INF.0b013e3182480fed
Source: PubMed

ABSTRACT The incidence of pneumococcal disease in sickle cell disease declined significantly with penicillin prophylaxis as well as with the pneumococcal polysaccharide and heptavalent conjugate vaccines. In this report, we describe our experience with pneumococcal bacteremia in pediatric patients with sickle cell disease in the post-heptavalent pneumococcal conjugate vaccine era. Despite established prophylactic strategies, pneumococcal bacteremia continues to occur in patients with sickle cell disease.

1 Bookmark
 · 
108 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Sepsis is the most common cause of mortality in sickle cell disease (SCD). Empiric antibiotic administration after obtaining blood cultures in febrile children with SCD has been a standard practice parameter. Objective: Our primary objective was to calculate the rate of bacteremia in febrile pediatric patients with SCD. Our secondary objective was to establish whether vital signs or diagnostics predict bacteremia in these patients. Methods: We conducted a retrospective chart review of patients with SCD who presented to an urban pediatric emergency department in Newark, NJ between January 1, 2001 and June 30, 2011 with the chief complaint of fever. Patients between the ages of 0 and 20 years with SCD who presented with the chief complaint of fever and who had a blood culture performed were included. Descriptive data, visitspecific data, and diagnostic data were collected. Results: Charts of 307 patients were included. Six patients had a positive blood culture, one of which was considered a true pathogen (Streptococcus pneumoniae) (0.33%; 95% confidence interval 0.06%-1.86%). There was no statistical significance between the means of visit-specific and diagnostic data of patients with positive blood cultures and those with negative blood cultures. Conclusions: The incidence of bacteremia in febrile children with SCD presenting to the emergency department is low. Close follow-up within 24 hours and delayed antibiotic administration can be a plausible alternative treatment option in this population. (C) 2014 Elsevier Inc.
    Journal of Emergency Medicine 08/2014; 47(4). DOI:10.1016/j.jemermed.2014.06.025 · 1.18 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Chronic pulmonary diseases describe chronic diseases that affect the airways and lung parenchyma. Examples of common chronic pulmonary diseases include asthma, bronchiectasis, chronic obstructive lung disease, lung fibrosis, sarcoidosis, pulmonary hypertension and cor pulmonale. Pulmonary infection is considered a significant cause of mortality in patients with chronic pulmonary diseases. Streptococcus pneumoniae is the leading isolated bacteria from adult patients with community-acquired pneumonia, the most common pulmonary infection. Vaccination against S. pneumoniae can reduce the risk of mortality especially from more serious infections in both immunocompetent and immunocompromised patients. Patients with chronic pulmonary diseases who take steroids or immunomodulating therapy (e.g., methotrexate, anti-TNF inhibitors), having concurrent sickle cell disease or other hemoglobinopathies, primary immunodeficiency disorders, human immunodeficiency virus infection / acquired immunodeficiency syndrome (HIV/AIDS), nephrotic syndrome, and hematologic or solid malignancies should be vaccinated with both 13-valent pneumococcal conjugate vaccine (PCV13) and the pneumococcal polysaccharide vaccine 23-valent (PPSV23).
    The American Journal of Medicine 09/2014; 127(9). DOI:10.1016/j.amjmed.2014.05.010 · 5.30 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Sickle cell disease (SCD) confers an increased risk of invasive pneumococcal disease, especially among young children. Pneumococcal vaccination decreases this risk, but the completion rate of age-appropriate vaccinations is not well defined in SCD. The goal of this study was to assess whether pneumococcal vaccines are administered to high-risk children with SCD according to recommended vaccine schedules. A case-control design was used to conduct this study. Administrative data were obtained on Michigan Medicaid or Children's Special Health Care Services programs enrollees. In addition, Michigan Newborn Screening and Michigan Care Improvement Registry records were used to confirm diagnosis and vaccine administration. This study compared pneumococcal vaccination rates in a cohort of 179 children with SCD with 537 age-matched non-SCD controls (1:3) enrolled in the Michigan Medicaid Program between 2001 and 2008. Study subjects were born in the state of Michigan between 2001 and 2005. The main outcome measure was the proportion of children defined as up to date for pneumococcal vaccines at defined milestone ages. Children with SCD had significantly higher vaccination rates than controls, yet these values were much lower than state and national immunization survey rates. Barriers to completing age-appropriate recommended pneumococcal immunizations should be identified and addressed to further reduce invasive pneumococcal disease in this high-risk patient population.
    Journal of public health management and practice: JPHMP 11/2013; 20(6). DOI:10.1097/PHH.0000000000000034 · 1.47 Impact Factor